Evidence map›Paper›PMID 40227775›Full record

ArticleCancers2025

Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation.

Martin Faehling, Sabine Fallscheer, Birgit Schwenk, Harald Seifarth, Jörn Sträter, Claudia Lengerke, Petros Christopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Martin FaehlingClinic of Cardiology and Pneumology, Esslingen Hospital, 73730 Esslingen, Germany.ORCID 0000-0002-2439-7538
Sabine FallscheerClinic of Cardiology and Pneumology, Esslingen Hospital, 73730 Esslingen, Germany.
Birgit SchwenkClinic of Cardiology and Pneumology, Esslingen Hospital, 73730 Esslingen, Germany.
Harald SeifarthClinic of Radiology, University of Münster, 48143 Münster, Germany.
Jörn SträterInstitute of Pathology, 73730 Esslingen, Germany.ORCID 0000-0002-0752-7169
Claudia LengerkeUniversity Hospital Tübingen, Department for Internal Medicine II, University of Tübingen, 72076 Tübingen, Germany.ORCID 0000-0001-5442-2805
Petros ChristopoulosDepartment of Medical Oncology, Thorax Clinic, 69126 Heidelberg, Germany.ORCID 0000-0002-7966-8980

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of lung adenocarcinoma has changed and now includes checkpoint inhibitors (CPIs) or, in the case of an

methodsThis real-world analysis (KOMPASS study) included stage IV lung-adenocarcinoma patients with either EGFR, KRAS, or no mutation. Patients were assigned to the "current"

resultsBoth the current and the historic

conclusionsA comparison of our data with that of the phase III trials KEYNOTE-189 and FLAURA suggests that the improved outcomes are due to the use of CPIs or osimertinib. The clinical trial results are well translated into real-world clinical practice with comparable OS.

Indexed as

check point inhibitorEGFRExon 21G12DKRASlung canceroverall survivalreal-world data

Identifiers

PMID40227775
PMCPMC11988053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.